VYGR / Voyager Therapeutics, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 1, 2026 Voyager Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 1, 2026 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission

Voyager Reports First Quarter 2026 Financial and Operating Results - VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP to

EXHIBIT 99.1 Voyager Reports First Quarter 2026 Financial and Operating Results - VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - - Ended Q1 2026 with cash position of $172 million, runway into 2028 - LEXINGTON, Mass., May 7, 2026 - Voyager Therapeutics, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2026 Voyager Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2026 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission

EMPLOYMENT AGREEMENT

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made as of December 4, 2025 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Gregory Shiferman (the “Executive”). 1.Employment. The Company and the Executive desire that the Executive be employed as the Company’s Senior Vice President and General Counsel. On or shortly following th

VOYAGER THERAPEUTICS, INC NON-STATUTORY STOCK OPTION AGREEMENT

Exhibit 10.3 VOYAGER THERAPEUTICS, INC NON-STATUTORY STOCK OPTION AGREEMENT Voyager Therapeutics, Inc. (the “Company”) hereby grants the following non-statutory stock option pursuant to its 2025 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Number of shares of the Company’s Common Stock subje

VOYAGER THERAPEUTICS, INC STOCK OPTION AGREEMENT

Exhibit 10.2 VOYAGER THERAPEUTICS, INC STOCK OPTION AGREEMENT Voyager Therapeutics, Inc. (the “Company”) hereby grants the following stock option pursuant to its 2025 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Incentive Stock Option or Nonstatutory Stock Option: Number of shares of the Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 Voyag

VOYAGER THERAPEUTICS, INC. RESTRICTED STOCK UNIT AGREEMENT

Exhibit 10.4 VOYAGER THERAPEUTICS, INC. RESTRICTED STOCK UNIT AGREEMENT Voyager Therapeutics, Inc. (the “Company”) hereby grants the following restricted stock units to the recipient named below pursuant to its 2025 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof and incorporated herein by reference. Notice of Grant Name of recipient (the “Participant”): Grant

ARS

2025 ANNUAL REPORTUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37625 Voyager Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 15, 2026 Voyager Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 15, 2026 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1

UNITED STATES

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37625 Voyager Therapeutics, Inc.

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.

EXHIBIT 99.1 Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 - - Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody sup

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 9, 2026 Voyager Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 9, 2026 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissio

RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT

Exhibit 10.39 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT This RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT (together with all Exhibits, “Agreement”), effe

SUBSIDIARIES OF THE REGISTRANT

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Voyager Securities Corporation Massachusetts

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 9, 2026 Voyager Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 9, 2026 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commis

Leveraging Genetics to Treat Neurological Diseases Corporate Deck / January 2026

Exhibit 99.1 Leveraging Genetics to Treat Neurological Diseases Corporate Deck / January 2026 2 | Forward - Looking Statements This presentation contains forward - looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws . The use of words such as “anticipate,” “expect,” “believe,” “plan,” “estima

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2026 Voyager Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2026 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commiss

Dear fellow stakeholders,

Exhibit 99.2 Dear fellow stakeholders, I want to take a moment to share why 2026 is a pivotal year in Voyager’s journey to become a premier multi-modality neurotherapeutics company. In particular, I see three principal pillars of value emerging this year: 1. Transformative year for tau, with two shots on goal · Biogen’s antisense oligonucleotide BIIB080 laid a compelling foundation for tau targeti

Up to $100,000,000 Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(3)  Registration No. 333-291418 PROSPECTUS Up to $100,000,000 Common Stock We have entered into a sales agreement with TD Securities (USA) LLC, or TD Cowen, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common st

VOYAGER THERAPEUTICS, INC. 75 Hayden Avenue Lexington, MA 02421

VOYAGER THERAPEUTICS, INC. 75 Hayden Avenue Lexington, MA 02421 November 26, 2025 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Voyager Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-291418 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities A

Security Type

Calculation of Filing Fee Tables S-3 Voyager Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward

As filed with the Securities and Exchange Commission on November 10, 2025

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 10, 2025 Registration No.

Form of Subordinated Note (FACE OF SECURITY)

Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE

VOYAGER THERAPEUTICS, INC. Dated as of _______________ SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE1

Exhibit 4.5 VOYAGER THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a)     6.09 310(b)     6.08 6.10 310(c)     Inapplicable 311(a)     6.13 311(b)     6.13 311(c)     Inapplicable 312(a)     4.01 4.04 312(b)     4.04(c) 312(c)     4.04(c) 313(a)     4.03 313(b)    

VOYAGER THERAPEUTICS, INC. Dated as of _______________ SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1

Exhibit 4.4 VOYAGER THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a)     6.09 310(b)     6.08 6.10 310(c)     Inapplicable 311(a)     6.13 311(b)     6.13 311(c)     Inapplicable 312(a)     4.01 4.04 312(b)     4.04(c) 312(c)     4.04(c) 313(a)     4.03 313(b)     4.03 3

Voyager Reports Third Quarter 2025 Financial and Operating Results - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™

EXHIBIT 99.1 Voyager Reports Third Quarter 2025 Financial and Operating Results - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration - - Ended 3Q25 with cash position of $229 million, maintaining runway into 2028 - LEX

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 10, 2025 Voyager Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 10, 2025 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 V

Voyager Therapeutics, Inc. SALES AGREEMENT

Exhibit 1.2 Voyager Therapeutics, Inc. SALES AGREEMENT November 10, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Voyager Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1.            Issuance and Sale of Shares. The Company agrees that, fro

Form of Senior Note (FACE OF SECURITY)

Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE

144

144 0001842523 XXXXXXXX LIVE 0001640266 Voyager Therapeutics, Inc. 001-37625 75 HAYDEN AVENUE LEXINGTON MA 02421 857-259-5340 Jorgensen Nathan D. Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 7666 36633.51 55468806 10/03/2025 NASDAQ Common 10/01/2025 Restricted Stock Vesting Issuer N 7666 10/01/2025 Compensation Y Sale includes an amount necessary to cover a t

144

144 0001984647 XXXXXXXX LIVE 0001640266 Voyager Therapeutics, Inc. 001-37625 75 HAYDEN AVENUE LEXINGTON MA 02421 857-259-5340 Fahey Sandell Jacquelyn Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 5843 27936.55 55468806 10/03/2025 NASDAQ Common 10/01/2025 Restricted Stock Vesting Issuer N 5843 10/01/2025 Compensation Y Sale includes an amount necessary to cover

Leveraging Genetics to Treat Neurological Diseases Citi 2025 Biopharma Back to School Conference September 2, 2025

Exhibit 99.1 Leveraging Genetics to Treat Neurological Diseases Citi 2025 Biopharma Back to School Conference September 2, 2025 2 | Forward - Looking Statements This presentation contains forward - looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws . The use of words such as “anticipate,” “e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 2, 2025 Voyager Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 2, 2025 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2025 Voyager Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2025 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 Voyage

Voyager Reports Second Quarter 2025 Financial and Operating Results - Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer’s dise

EXHIBIT 99.1 Voyager Reports Second Quarter 2025 Financial and Operating Results - Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer’s disease franchise - - 11 partnered programs with potential for $2.6B in development-stage milestone payments - LEXINGTON, Mass., August 6, 20

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Voyager Therapeutics, Inc.

As filed with the Securities and Exchange Commission on June 9, 2025

As filed with the Securities and Exchange Commission on June 9, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 3, 2025 Voyager Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 3, 2025 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission

Voyager Reports First Quarter 2025 Financial and Operating Results - Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e1

EXHIBIT 99.1 Voyager Reports First Quarter 2025 Financial and Operating Results - Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg - - Recent Voyager data on VY7523 and VY1706 presented at AD/PD™ 2025 continue to support tau as next critical target in Alzheime

Form of Performance Restricted Stock Unit Award Agreement.

Exhibit 10.1 PERFORMANCE RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER VOYAGER THERAPEUTICS, INC. 2015 STOCK OPTION AND INCENTIVE PLAN Pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Voyager Therapeutics, Inc. (the “Company”) hereby grants an award of the number of Performance Restricted Stock Unit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 Voyag

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2025 Voyager Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2025 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission

Second Amendment to Option and License Agreement, by and between the Company and AstraZeneca Ireland Limited, dated as of March 15, 2025.

Exhibit 10.2 Second Amendment to Option and License Agreement This Second Amendment to Option and License Agreement (this “Amendment”) is entered into and made effective as of March 15, 2025 (the “Amendment Effective Date”) by and between (i) Voyager Therapeutics, Inc., a Delaware corporation having its principal place of business at 75 Hayden Avenue, Lexington, MA 02421 (“Voyager”), and (ii) Astr

ARS

ĐĐ Ď Đ Ē ANNUAL REPORT>7KLVSDJHLQWHQWLRQDOO\OHIWEODQN@UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37625 Voyager Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14

Subsidiaries of the Registrant.

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Voyager Securities Corporation Massachusetts

As filed with the Securities and Exchange Commission on March 11, 2025

As filed with the Securities and Exchange Commission on March 11, 2025 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Voyager Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2025 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi

Amended and Restated Insider Trading Policy

Exhibit 19.1 VOYAGER THERAPEUTICS, INC. Amended and Restated Insider Trading Policy 1. Background and purpose 1.1Why Have We Adopted This Insider Trading Policy? The federal securities laws prohibit any member of the Board of Directors (a “Director”), officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934 (the “Exchange Act”), an “executive officer”), or employee of Voyager

UNITED STATES

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37625 Voyager Therapeutics, Inc.

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - A

EXHIBIT 99.1 Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging d

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 11, 2025 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi

VYGR / Voyager Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

SC 13G/A 1 armistice-vygr093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Voyager Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 92915B106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the

VYGR / Voyager Therapeutics, Inc. / EcoR1 Capital, LLC Passive Investment

SC 13G/A 1 vygr13ga4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Voyager Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 92915B106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appr

Voyager Reports Third Quarter 2024 Financial and Operating Results –Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025– –Recent third-party cl

EXHIBIT 99.1 Voyager Reports Third Quarter 2024 Financial and Operating Results –Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025– –Recent third-party clinical data establish that an antibody can inhibit tau accumulation in the human brain; provide support for use of an antibody to target

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 V

First Amendment to Option and License Agreement, by and between Registrant and Novartis Pharma AG, dated September 3, 2024.

Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. EXECUTION VERSION CONFIDENTIAL FIRST AMENDMENT TO OPTION AND LICENSE AGREEMENT This First Amendment to Option and License Agreement (this “Amendment”) is enter

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 12, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi

First Amendment to Option and License Agreement, by and between Registrant and AstraZeneca Ireland Limited, dated September 30, 2024.

Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. First Amendment to Option and License Agreement This First Amendment to Option and License Agreement (this “Amendment”) is entered into and made effective as o

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 3, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi

VYGR / Voyager Therapeutics, Inc. / BlackRock Inc. Passive Investment

SC 13G/A 1 us92915b1061080724.txt us92915b1061080724.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Voyager Therapeutics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 92915B106 - (CUSIP Number) July 31, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2024 Voyager Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 Voyage

As filed with the Securities and Exchange Commission on August 6, 2024

As filed with the Securities and Exchange Commission on August 6, 2024 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Voyager Therapeutics, Inc.

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results – Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer’s disease – – Three

EXHIBIT 99.1 Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results – Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer’s disease – – Three CNS gene therapy programs on track for INDs in 2025 following development candidate nominations for GBA1 and FA programs and pre-IND mee

First Amendment to Collaboration Agreement, by and between Registrant and Neurocrine Biosciences, Inc., dated April 3, 2024.

Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This FIRST AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (this“Amendment”) is effective as of Apr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 11, 2024 Voyager Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 11, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissio

Employment Agreement, by and between Voyager Therapeutics, Inc. and Nathan Jorgensen, Ph.D., M.B.A., effective as of July 8, 2024.

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made as of July 8, 2024 (the “Effective Date”) by and between (i) Voyager Therapeutics, Inc., a Delaware corporation with an address at 75 Hayden Avenue, Lexington, MA 02421 (the “Company”) and (ii) Nathan Jorgensen, Ph.D., MBA, an individual with an address at [**] (the “Executive”). 1.            Employment. The Co

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 5, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results – Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single ascending dose t

EXHIBIT 99.1 Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results – Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single ascending dose trial in the coming weeks – – Development candidates selected for Neurocrine-partnered GBA1 and Friedreich’s Ataxia gene therapy programs;

Consulting Agreement by and between the Registrant and Peter P. Pfreundschuh, dated as of May 6, 2024

Exhibit 10.4 Execution Version CONSULTING AGREEMENT THIS AGREEMENT (together with the attached Services Form, the “Agreement”), is entered into as of May 6, 2024 (the “Effective Date”), by and between Peter P. Pfreundschuh, an individual (the “Consultant”), and Voyager Therapeutics, Inc., a Delaware corporation located at 75 Hayden Avenue, Lexington, MA 02421 (hereinafter “Voyager”). WHEREAS, Voya

Amendment No. 4 to Consulting Agreement by and between the Registrant and Dinah Sah, Ph.D., dated as of February 1, 2024.

Exhibit 10.1 AMENDMENT NO. 4 TO CONSULTING AGREEMENT This Amendment No. 4 to Consulting Agreement (this “Amendment”) effective as of February 1, 2024 (“Amendment Effective Date”) is entered into by and between (i) Voyager Therapeutics, Inc., a Delaware corporation with an office located at 75 Hayden Avenue, Lexington, MA 02421 (“Voyager”) and (ii) Dinah Sah, Ph.D., an individual residing at [**] (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 Voyag

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 13, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14

ARS

2023 ANNUAL REPORTCNS Pipeline Advances towards Clinical Trials VY-TAU01, Voyager’s most advanced program, is an antibody targeting pathological tau.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 27, 2024 Voyager Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 27, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi

Transition, Separation and Release of Claims Agreement, by and between the Registrant and Peter P. Pfreundschuh, dated April 1, 2024.

Exhibit 10.1 Execution Version TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENT This Transition, Separation and Release of Claims Agreement (this “Agreement”) is made as of the Agreement Effective Date (as defined below) by and between Voyager Therapeutics, Inc. (the “Company”) and Peter P. Pfreundschuh (“Executive”) (together, the “Parties”). WHEREAS, the Company and Executive are parties t

Employment Agreement, by and between the Registrant and Toby Ferguson, M.D., Ph.D., dated as of February 29, 2024.

Exhibit 10.1 Execution Version EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made as of February 29, 2024 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Toby Ferguson, M.D., Ph.D. (the “Executive”). 1.            Employment. The Company and the Executive desire that the Executive be employed as the Company’s Chief Medical Officer. The em

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 29, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi

As filed with the Securities and Exchange Commission on February 28, 2024

As filed with the Securities and Exchange Commission on February 28, 2024 Registration No.

License and Collaboration Agreement by and between Registrant and Novartis Pharma AG, dated December 28, 2023

Exhibit 10.43 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LICENSE AND COLLABORATION AGREEMENT By and between VOYAGER THERAPEUTICS, INC. AND NOVARTIS PHARMA, AG December 28, 2023 TABLE OF CONTENTS Pa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 28, 2024 Voyager Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 28, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi

Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results – Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $1

EXHIBIT 99.1 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results – Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering – – Strong cash position and anticipated milestones/reimbursements provide runway into 2027, potentially enabl

Amendment No. 2 to the Consulting Agreement, by and between the Registrant and Dinah Sah, Ph.D., dated June 27, 2022

Exhibit 10.46 AMENDMENT NO. 2 CONSULTING AGREEMENT Amendment No. 2 (this “Amendment”) to the Consulting Agreement, between Dinah Sah (“Consultant”) and Voyager Therapeutics, Inc. (“Voyager”) effective as of June 28, 2019 (the “Effective Date”) as amended by Amendment No. 1 to the Consulting Agreement, effective as of September 16, 2019 (together, the “Agreement”), is entered into as of June 27, 20

Amendment No. 3 to the Consulting Agreement, by and between the Registrant and Dinah Sah, Ph.D., dated May 1, 2023

Exhibit 10.47 AMENDMENT NO. 3 TO CONSULTING AGREEMENT This Amendment No. 3 to Consulting Agreement (this ”Amendment”) effective as of May 1, 2023 (“Amendment Effective Date”) is entered into by and between (i) Voyager Therapeutics, Inc., a Delaware corporation with an office located at 64 Sidney Street, Cambridge, MA 02139 (“Voyager”) and (ii) Dinah Sah, Ph.D., an individual residing at 15 Huckleb

UNITED STATES

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37625 Voyager Therapeutics, Inc.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Voyager Therapeutics, Inc.

Compensation Recovery Policy

Exhibit 97.1 VOYAGER THERAPEUTICS, INC. Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Voyager Therapeutics, Inc. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”). This Policy is effective as of October 2, 2023 (the “Effective Date”). 1.Definitions (a)“Accounting Restatement” means a requirement that the Company prepare an acco

Stock Purchase Agreement by and between Registrant and Novartis Pharma AG, dated December 28, 2023

Exhibit 10.44 EXECUTIBE VERSION STOCK PURCHASE AGREEMENT By and Between NOVARTIS PHARMA AG AND VOYAGER THERAPEUTICS, INC. Dated as of December 28, 2023 TABLE OF CONTENTS Page 1. Definitions 1 1.1 Defined Terms 1 1.2 Additional Defined Terms 4 2. Purchase and Sale of Common Stock 5 3. Closing Date; Deliveries 6 3.1 Closing Date 6 3.2 Deliveries 6 4. Representations and Warranties of the Company 6 4

Investor Agreement by and between Registrant and Novartis Pharma AG, dated December 28, 2023

Exhibit 10.45 EXECUTION VERSION INVESTOR AGREEMENT By and Between NOVARTIS PHARMA AG AND VOYAGER THERAPEUTICS, INC. Dated as of December 28, 2023 TABLE OF CONTENTS 1. Definitions 1 2. Restrictions on Beneficial Ownership 5 3. Restrictions on Dispositions 6 3.1 Lock-Up 6 3.2 Certain Tender Offers 7 3.3 Sale Limitations 7 3.4 Offering Lock-Up 7 3.5 Transactions for Personal Account; Change of Contro

Subsidiaries of the Registrant.

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Voyager Securities Corporation Massachusetts

VYGR / Voyager Therapeutics, Inc. / Third Rock Ventures III, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 d791499dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* Voyager Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement)

VYGR / Voyager Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

SC 13G/A 1 armistice-vygr123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Voyager Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the a

VYGR / Voyager Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv02243-voyagertherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Voyager Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 92915B106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t

VYGR / Voyager Therapeutics, Inc. / BlackRock Inc. Passive Investment

SC 13G 1 us92915b1061012924.txt us92915b1061012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Voyager Therapeutics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 92915B106 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriat

Form of Pre-Funded Warrant

Exhibit 4.1 VOYAGER THERAPEUTICS, Inc. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: January [], 2024 Voyager Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] or its registered assigns (the “Holde

Underwriting Agreement, dated January 4, 2024, by and among Voyager Therapeutics, Inc. and Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein.

Exhibit 1.1 7,777,778 Shares Pre-Funded Warrants to Purchase 3,333,333 Shares Voyager Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENT January 4, 2024 Citigroup Global Markets Inc. Guggenheim Securities, LLC As Representatives of the several Underwriters c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Guggenheim Securities, LLC 330 Madison Ave New York, Ne

7,777,778 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 3,333,333 Shares of Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-268240 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED NOVEMBER 15, 2022) 7,777,778 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 3,333,333 Shares of Common Stock We are offering 7,777,778 shares of our common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase up

Voyager Therapeutics, Inc. • 75 Hayden Avenue, Lexington, MA 02421 • 857.259.5340 • voyagertherapeutics.com

Exhibit 99.1 Voyager Therapeutics Announces Pricing of Public Offering LEXINGTON, Mass., JANUARY 4, 2024 – Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the pricing of an underwritten public offering of 7,777,778 shares of its common stock at a public offering price of $9.00 per share, and, to investors who so choo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 3, 2024 Voyager Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 3, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commiss

SUBJECT TO COMPLETION, DATED JANUARY 4, 2024

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 28, 2023 Voyager Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 28, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 6, 2023 Voyager Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 6, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commis

Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program - IND filing expected in mid-2025 -

Exhibit 99.1 Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program - IND filing expected in mid-2025 - LEXINGTON, Mass., DECEMBER 6, 2023 – Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead develop

Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results - GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing - - SOD1 ALS gene therapy program on tr

EXHIBIT 99.1 Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results - GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing - - SOD1 ALS gene therapy program on track for development candidate selection by end of year – - Conference call at 4:30 p.m. ET today - LEXINGTON, Mass., November 6, 2023 – V

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 V

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2023 Voyager Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commiss

First Amendment to Lease Agreement, by and between Registrant and LS 75 Hayden, LLC, dated August 11, 2023.

Exhibit 10.1 75 HAYDEN AVENUE LEXINGTON, MASSACHUSETTS 02421 (the “Building”) FIRST AMENDMENT (“First Amendment”) EFFECTIVE DATE: August 11, 2023 LANDLORD: LS 75 HAYDEN, LLC, a Delaware limited liability company, as successor-in-interest to HCP/King 75 Hayden LLC, a Delaware limited liability company TENANT: VOYAGER THERAPEUTICS, INC., a Delaware corporation EXISTING PREMISES: Areas on the first (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 Voyage

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 3, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi

Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results - Introduced new vectorized anti-Aβ antibody gene therapy research initiative, expanding Alzheimer’s disease portfolio - - Executed license agreement with Sangamo for pr

EXHIBIT 99.1 Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results - Introduced new vectorized anti-Aβ antibody gene therapy research initiative, expanding Alzheimer’s disease portfolio - - Executed license agreement with Sangamo for prion disease treatment - - Presented validating preclinical results including increased brain transduction of IV-administered TRACER™ caps

Employment Agreement by and between the Registrant and Jacquelyn Fahey Sandell, effective as of July 5, 2023

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made as of July 5, 2023 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Jacquelyn Fahey Sandell (the “Executive”). 1.            Employment. The Company and the Executive desire that the Executive be employed as the Company’s Chief Legal Officer. The employment relationship betwee

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 5, 2023 Voyager Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 5, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 6, 2023 Voyager Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 6, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission

Consulting Agreement, by and between the Registrant and Robert W. Hesslein, dated April 28, 2023

Exhibit 10.5 CONSULTING AGREEMENT THIS AGREEMENT (together with the attached Accounting of Services Form, the “Agreement”), is entered into as of April 29, 2023 (the “Effective Date”), by and between Robert W. Hesslein, an individual (the “Consultant”), and Voyager Therapeutics, Inc., a Delaware corporation located at 64 Sidney Street, Cambridge, MA 02139 (hereinafter “Voyager”). WHEREAS, Voyager

Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results - Neurocrine Biosciences strategic collaboration and Novartis license option exercise demonstrate Voyager pipeline and platform value and strengthen balance sheet - - Alz

EXHIBIT 99.1 Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results - Neurocrine Biosciences strategic collaboration and Novartis license option exercise demonstrate Voyager pipeline and platform value and strengthen balance sheet - - Alzheimer’s disease franchise advances: selected lead candidate for anti-tau antibody program; IND submission on track for first half of 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2023 Voyager Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 Voyag

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2023 Voyager Therapeutics,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14

ARS

2022 ANNUAL REPORTThis page intentionally left blank.I believe we’re witnessing a renaissance in neurotherapeutics. Just this year, the second disease- OQFKH[KPIVJGTCR[HQT#N\JGKOGTŨUFKUGCUGTGEGKXGFCEEGNGTCVGF CRRTQXCNCPFVJGƒTUVFTWIYCU approved for Friedreich’s ataxia. We’ve seen breakthroughs in treating negative symptoms of UEJK\QRJTGPKCUQOGVJKPIHQTYJKEJVJGTGCTGPQCRRTQXGFVJ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2023 Voyager Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi

As filed with the Securities and Exchange Commission on March 7, 2023

As filed with the Securities and Exchange Commission on March 7, 2023 Registration No.

Patent and Know-How Licence between the Registrant and Touchlight IP Limited, dated as of November 3, 2022

Exhibit 10.43 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. DATED 3NOVEMBER 2022 PATENT AND KNOW-HOW LICENCE BETWEEN TOUCHLIGHT IP LIMITED AND VOYAGER THERAPEUTICS, INC. This agreement is dated 3 November 2022 Parties

Calculation of Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Voyager Therapeutics, Inc.

Subsidiaries of the Registrant.

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Voyager Securities Corporation Massachusetts

Amended and Restated Investor Agreement by and between the Registrant and Neurocrine Biosciences, Inc., dated as of January 8, 2023

Exhibit 10.46 EXECUTION VERSION AMENDED AND RESTATED INVESTOR AGREEMENT By and Between NEUROCRINE BIOSCIENCES, INC. AND VOYAGER THERAPEUTICS, INC. Dated as of January 8, 2023 TABLE OF CONTENTS 1. Definitions 1 2. Restrictions on Beneficial Ownership 6 3. Restrictions on Dispositions 7 3.1 Lock-Up 7 3.2 Certain Tender Offers 7 3.3 Sale Limitations 7 3.4 Offering Lock-Up 8 3.5 Transactions for Perso

Stock Purchase Agreement by and between the Registrant and Neurocrine Biosciences, Inc., dated as of January 8, 2023

Exhibit 10.44 EXECUTION VERSION STOCK PURCHASE AGREEMENT By and Between NEUROCRINE BIOSCIENCES, INC. AND VOYAGER THERAPEUTICS, INC. Dated as of January 8, 2023 TABLE OF CONTENTS Page 1. Definitions 1 1.1 Defined Terms 1 1.2 Additional Defined Terms 4 2. Purchase and Sale of Common Stock 5 3. Closing Date; Deliveries 5 3.1 Closing Date 5 3.2 Deliveries 5 4. Representations and Warranties of the Com

Option and License Agreement by and between the Registrant and Novartis Pharma AG, dated March 4, 2022

Exhibit 10.36 Execution Version Confidential Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. OPTION AND LICENSE AGREEMENT By and between VOYAGER THERAPEUTICS, INC. AND NOVARTIS PHARMA, A.G. March 4, 2022 TABLE OF CONTENT

Collaboration and License Agreement by and between the Registrant and Neurocrine Biosciences, Inc., dated as of January 8, 2023

Exhibit 10.45 EXECUTION COPY CONFIDENTIAL Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COLLABORATION AND LICENSE AGREEMENT by and between VOYAGER THERAPEUTICS, INC. AND NEUROCRINE BIOSCIENCES, INC. EXECUTION COPY CONF

Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results - Transformational progress in 2022 marked by reprioritization of high-value neurology pipeline and validation of TRACERTM novel capsid platform through tr

EXHIBIT 99.1 Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results - Transformational progress in 2022 marked by reprioritization of high-value neurology pipeline and validation of TRACERTM novel capsid platform through transactions with Pfizer and Novartis - - Partnering momentum continues into 2023 with $175 million payment associated with Neurocrine Bios

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 7, 2023 Voyager Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 7, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37625 Voyager Therapeutics, Inc.

VYGR / Voyager Therapeutics Inc / Neurocrine Biosciences Inc - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* VOYAGER THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 92915B106 (CUSIP Number) Kevin C. Gorman, Ph.D. Chief Executive Officer Neurocrine Biosciences, Inc. 12780 El Camino Real San Die

AMENDED AND RESTATED INVESTOR AGREEMENT By and Between NEUROCRINE BIOSCIENCES, INC. VOYAGER THERAPEUTICS, INC. Dated as of January 8, 2023

EX-99.1 Exhibit 99.1 AMENDED AND RESTATED INVESTOR AGREEMENT By and Between NEUROCRINE BIOSCIENCES, INC. AND VOYAGER THERAPEUTICS, INC. Dated as of January 8, 2023 TABLE OF CONTENTS 1.   Definitions 1 2.   Restrictions on Beneficial Ownership 6 3.   Restrictions on Dispositions 7 3.1   Lock-Up 7 3.2   Certain Tender Offers 7 3.3   Sale Limitations 7 3.4   Offering Lock-Up 8 3.5   Transactions for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 Voyager Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 22, 2023 Voyager Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 22, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi

Transition, Separation and Release of Claims Agreement, by and between the Company and Robert W. Hesslein, dated February 22, 2023.

Exhibit 10.1 Execution Version TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENT This Transition, Separation and Release of Claims Agreement (this “Agreement”) is made as of the Agreement Effective Date (as defined below) by and between Voyager Therapeutics, Inc. (the “Company”) and Robert W. Hesslein (“Executive”) (together, the “Parties”). WHEREAS, the Company and Executive are parties to t

VYGR / Voyager Therapeutics Inc / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

VYGR / Voyager Therapeutics Inc / Third Rock Ventures III, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 d420693dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* Voyager Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement)

VYGR / Voyager Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv02209-voyagertherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Voyager Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 92915B106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box

VYGR / Voyager Therapeutics Inc / EcoR1 Capital, LLC Passive Investment

SC 13G/A 1 voyagerthera13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Voyager Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 92915B106 (CUSIP Number) January 11, 2023 (Date of Event Which Requires Filing of this Statement) Check the

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commiss

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 13, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi

Up to $75,000,000 Common Stock

TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(3)? ?Registration No. 333-268240? PROSPECTUS ? Up to $75,000,000 Common Stock ? We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common s

VOYAGER THERAPEUTICS, INC. 64 Sidney Street Cambridge, MA 02139

VOYAGER THERAPEUTICS, INC. 64 Sidney Street Cambridge, MA 02139 November 10, 2022 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Voyager Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-268240 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities A

LETTER

United States securities and exchange commission logo November 9, 2022 Alfred Sandrock President and Chief Executive Officer Voyager Therapeutics, Inc.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Voyager Therapeutics, Inc.

Form of Subordinated Indenture

Exhibit 4.5 VOYAGER THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 8, 2022 Voyager Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 8, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commis

Sales Agreement, by and between the Registrant and Cowen and Company, LLC, dated November 8, 2022

Exhibit 1.2 Voyager Therapeutics, Inc. $75,000,000 Common STOCk SALES AGREEMENT November 8, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Voyager Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that,

Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results - Voyager’s TRACERTM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dose potential further validate TR

EXHIBIT 99.1 Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results - Voyager’s TRACERTM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER - - Pipeline programs advancing; development candidate selections for lead programs expected Q4 2022 to H1 2023 - - Conference call

Form of Senior Indenture

Exhibit 4.4 VOYAGER THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 V

Form of Subordinated Note

Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE

As filed with the Securities and Exchange Commission on November 8, 2022

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 8, 2022 Registration No.

Form of Senior Note

Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 4, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commiss

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 7, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi

Second Amended and Restated Employment Agreement by and between the Registrant and Todd Carter, Ph.D., effective as of September 7, 2022

Exhibit 10.2 ?? SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT ? This Second Amended and Restated Employment Agreement (this ?Agreement?) is made as of September?7, 2022 (the ?Effective Date?) by and between Voyager Therapeutics,?Inc. (the ?Company?) and Todd Carter, Ph.D. (the ?Executive?). ? WHEREAS, the Company and the Executive are parties to a certain Amended and Restated Employment Agreeme

Employment Agreement by and between the Registrant and Peter Pfreundschuh, effective as of September 7, 2022

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made as of September 7, 2022 (the ?Effective Date?) by and between Voyager Therapeutics, Inc. (the ?Company?) and Peter Pfreundschuh (the ?Executive?). 1.????????????Employment. The Company and the Executive desire that the Executive be employed as the Company?s Chief Financial Officer. The employment relationship be

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): August 4, 2022 ? ? Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? ? Delaware ? 001-37625 ? 46-3003182 (State or other jurisd

Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results Pipeline prioritizes tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's disease and SOD1-ALS, each program employing e

EXHIBIT 99.1 Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results ? Pipeline prioritizes tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's disease and SOD1-ALS, each program employing efficient paths to human proof of biology ? Targeting development candidate selection for priority programs in 2022 and H1 2023 ? Cross

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 27, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissio

Lease Termination Agreement by and between the Registrant and BRE-BMR Pilgrim & Sidney LLC, dated as of June 22, 2022

Exhibit 10.1 LEASE TERMINATION AGREEMENT THIS LEASE TERMINATION AGREEMENT (this ?Agreement?) is entered into as of this 22nd day of June, 2022 (?Effective Date?), by and between BRE-BMR Pilgrim & Sidney LLC, a Delaware limited liability company, as successor-in-interest to UP 45/75 Sidney Street, LLC (?Landlord?) and Voyager Therapeutics, Inc., a Delaware corporation (?Tenant?). RECITALS A.???????

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 22, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissio

Sublease Termination Agreement by and between the Registrant and BioNTech US, Inc., dated as of June 22, 2022

Exhibit 10.2 SUBLEASE TERMINATION AGREEMENT THIS SUBLEASE TERMINATION AGREEMENT (this ?Agreement?) is entered into as of this 22nd day of June, 2022 (?Effective Date?), by and between Voyager Therapeutics, Inc., a Delaware corporation (?Voyager?), and BioNTech US Inc., a Delaware corporation (?BioNTech?). RECITALS A.??????????WHEREAS, UP 45/75 Sidney Street, LLC, as predecessor to BRE-BMR Pilgrim

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 2, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission

Consulting Agreement by and between the Registrant and Glenn Pierce, M.D., Ph.D., effective as of June 6, 2022

Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (including the exhibits attached hereto, ?Agreement?), is entered into as of June 6, 2022 (?Effective Date?), by and between (i) Voyager Therapeutics, Inc., a Delaware corporation with an office at 64 Sidney Street, Cambridge, MA 02139 (?Voyager?) and (ii) Dr. Glenn Pierce, M.D., Ph.D., with an address of (?Consultant?). WHEREAS, Voyager

Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS tropisms of novel

EXHIBIT 99.1 Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results ? Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS tropisms of novel TRACERTM AAV9 and AAV5-derived capsids ? Preclinical data to be presented at the ASGCT Annual Meeting to demonstrate reduction of tumor

Financial Statements and Exhibits, Results of Operations and Financial Condition

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): May 4, 2022 ? ? Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? ? Delaware ? 001-37625 ? 46-3003182 (State or other jurisdict

Option and License Agreement by and between the Registrant and Novartis Pharma AG, dated March 4, 2022.

Execution Version Confidential Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

VYGR / Voyager Therapeutics Inc / EcoR1 Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Voyager Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 92915B106 (CUSIP Number) April 21, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 14, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi

Employment Agreement, by and between the Registrant and Alfred Sandrock, M.D., Ph.D., effective as of March 22, 2022.

Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made as of March 22, 2022 (the ?Effective Date?) by and between Voyager Therapeutics, Inc. (the ?Company?) and Alfred Sandrock, M.D., Ph.D. (the ?Executive?). 1. Employment. The Company and the Executive desire that the Executive be employed as the Company?s President and Chief Executive Officer. The employment relat

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 19, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi

Financial Statements and Exhibits, Results of Operations and Financial Condition

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): March 8, 2022 ? ? Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? ? Delaware ? 001-37625 ? 46-3003182 (State or other jurisdi

Calculation of Filing Fee Tables.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Voyager Therapeutics, Inc.

Consulting Agreement by and between the Registrant and Allison Dorval, dated as of November 26, 2021

Exhibit 10.38 CONSULTING AGREEMENT ? THIS AGREEMENT (together with the attached Accounting of Services Form, the ?Agreement?), is entered into as of November 26, 2021 (the ?Effective Date?), by and between Allison Dorval, an individual (the ?Consultant?), and Voyager Therapeutics, Inc., a Delaware corporation located at 75 Sidney Street, Cambridge, MA 02139 (hereinafter ?Voyager?). ? WHEREAS, Voya

As filed with the Securities and Exchange Commission on March 8, 2022

As filed with the Securities and Exchange Commission on March 8, 2022 Registration No.

Subsidiaries of the Registrant.

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT ? ? ? Name of Entity State/Country of Organization ? ? ? Voyager Securities ? Corporation Massachusetts ?

Separation and Release of Claims Agreement by and between the Registrant and Allison Dorval, effective December 13, 2021

Exhibit 10.37 SEPARATION AND RELEASE OF CLAIMS AGREEMENT This Separation and Release of Claims Agreement (this ?Agreement?) is made as of the Agreement Effective Date (as defined below) by and between Voyager Therapeutics, Inc. (the ?Company?) and Allison Dorval (?Executive?) (together, the ?Parties?). WHEREAS, the Company and Executive are parties to the Employment Agreement dated as of November

Employment Agreement, by and between the Registrant and Julie Burek, dated as of October 1, 2021

Exhibit 10.39 ? ? EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made as of October 1, 2021 (the ?Agreement Date?) by and between Voyager Therapeutics, Inc. (the ?Company?) and Julie Burek (the ?Executive?). 1.Employment. The Company and the Executive acknowledge and agree that: (a) the Executive has been employed by the Company since April 2, 2018 (the ?Employment Date?), an

UNITED STATES

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? ? FORM 10-K ? ? (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number: 001-37625 ? ? Voyager Therapeutics, Inc.

Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results License option agreement with Novartis for target-specific access to TRACERTM next-generation AAV capsids for potential use with three CNS targets plus opt

EXHIBIT 99.1 Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results ? License option agreement with Novartis for target-specific access to TRACERTM next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets ? Novartis agreement marks second recent major transaction to leverage Voyager?s TRAC

CT ORDER

AGREEMENT

Exhibit A AGREEMENT The undersigned agree that this Amendment No. 2 to Schedule 13G dated February 14, 2022 relating to the Common Stock, $0.001 par value, of Voyager Therapeutics, Inc. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd

VYGR / Voyager Therapeutics Inc / ARMISTICE CAPITAL, LLC - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

VYGR / Voyager Therapeutics Inc / EcoR1 Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Voyager Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t

VYGR / Voyager Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment

United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* VOYAGER THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this

VYGR / Voyager Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Voyager Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 92915B106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 1, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commis

Amended and Restated Employment Agreement, by and between the Registrant and Robin Swartz, effective as of February 7, 2022

Exhibit 10.2 EXECUTION VERSION AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this ?Agreement?) is made as of February 7, 2022 (the ?Effective Date?) by and between Voyager Therapeutics, Inc. (the ?Company?) and Robin Swartz (the ?Executive?). WHEREAS, the Company and the Executive are parties to a certain Employment Agreement dated January 11, 2021 (the

Consulting Agreement by and between the Registrant and Alfred Sandrock, effective as of February 7, 2022

Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (including the exhibits attached hereto, this ?Agreement?), effective as of February 7, 2022 (the ?Effective Date?), is entered into by and between (i) Voyager Therapeutics, Inc., a Delaware corporation with an office at 75 Sidney Street, Cambridge, MA 02139 (?Voyager?) and (ii) Alfred Sandrock, Jr., M.D., Ph.D., an individual residing at

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 16, 2021 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi

Sublease Agreement, by and between Registrant and BioNTech US Inc., dated September 3, 2021

SUBLEASE AGREEMENT ? ? THIS SUBLEASE AGREEMENT (this ?Sublease?) is made and entered into as of September 3, 2021 (the ?Effective Date?), by and between VOYAGER THERAPEUTICS, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): November 2, 2021 ? ? Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? ? Delaware ? 001-37625 ? 46-3003182 (State or other juri

Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results License option agreement with Pfizer provides Voyager $30M up front and up to $600M in potential exercise fees and milestones payments plus royalties in exchange for acce

EXHIBIT 99.1 Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results ? License option agreement with Pfizer provides Voyager $30M up front and up to $600M in potential exercise fees and milestones payments plus royalties in exchange for access to TRACER? novel capsids for use with two Pfizer transgenes in neurologic and cardiovascular disease ? TRACER platform identifies AA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Option and License Agreement, by and between the Registrant and Pfizer Inc., dated October 1, 2021

Exhibit 10.2 EXECUTION VERSION Confidential Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. OPTION AND LICENSE AGREEMENT By and between VOYAGER THERAPEUTICS, INC. AND PFIZER INC. October 1, 2021 ? ? ? ? TABLE OF CONTENTS

VYGR / Voyager Therapeutics Inc / EcoR1 Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Voyager Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 92915B106 (CUSIP Number) October 12, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 1, 2021 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commiss

Financial Statements and Exhibits, Results of Operations and Financial Condition

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): August 9, 2021 ? ? Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? ? Delaware ? 001-37625 ? 46-3003182 (State or other jurisd

Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACERTM AAV Capsid and Vectorized Antibody Platform Technologies Proprietary AAV capsids to power second-generation efforts in Huntington’s disease and ALS, pre-cli

EXHIBIT 99.1 ? Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACERTM AAV Capsid and Vectorized Antibody Platform Technologies Proprietary AAV capsids to power second-generation efforts in Huntington?s disease and ALS, pre-clinical programs in spinal muscular atrophy and diseases linked to GBA1 mutations Increased platform investment to expand discovery of no

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

VYGR / Voyager Therapeutics Inc / BlackRock Inc. Passive Investment

us92915b1061071021.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) Voyager Therapeutics Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 92915B106 - (CUSIP Number) June 30, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 3, 2021 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission

Amendment No. 1 to Employment Agreement, by and between the Registrant and Glenn Pierce, dated June 7, 2021

Exhibit 10.1 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (this ?Amendment?) is made as of June 7, 2021 (the ?Amendment Effective Date?) by and between Voyager Therapeutics, Inc. (the ?Company?) and Glenn Pierce (the ?Executive?). Any capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Agreement (as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin

Employment Agreement, by and between the Registrant and Michael Higgins, dated May 19, 2021

EX-10.2 3 tm2116931d1ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 EXECUTION COPY EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made as of May 19, 2021 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Michael Higgins (the “Executive”). 1. Employment. The Company and the Executive desire that the Executive be employed as the Company’s interim Presid

Transition, Separation and Release of Claims Agreement, by and between the Registrant and G. Andre Turenne, dated May 19, 2021.

Exhibit 10.1 EXECUTION COPY TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENT This Transition, Separation and Release of Claims Agreement (the ?Agreement?) is made as of the Agreement Effective Date (as defined below) by and between Voyager Therapeutics, Inc. (the ?Company?) and Gaetan Andre Turenne (?Executive?) (together, the ?Parties?). WHEREAS, the Company and Executive are parties to the

Employment Agreement, by and between the Registrant and Glenn Pierce, M.D., Ph.D., dated May 19, 2021

Exhibit 10.3 EXECUTION COPY EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made as of May 19, 2021 (the ?Effective Date?) by and between Voyager Therapeutics, Inc. (the ?Company?) and Glenn Pierce (the ?Executive?). 1. Employment. The Company and the Executive desire that the Executive be employed as the Company?s interim Chief Scientific Officer. The employment relationship

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 14, 2021 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission

Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates - On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington’s disease in the fourth quarter of 2021 - 8 presentations at American Society of Gene and Cell

EXHIBIT 99.1 Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates ? - On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington?s disease in the fourth quarter of 2021 - 8 presentations at American Society of Gene and Cell Therapy (ASGCT) conference, including new data on next generation blood brain barrier penetrant capsids - Virtual investor and analyst

Financial Statements and Exhibits, Results of Operations and Financial Condition

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): May 10, 2021 ? ? Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? ? Delaware ? 001-37625 ? 46-3003182 (State or other jurisdic

Quarterly Report - 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

- DEF 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule

-

begin 644 filename1 M)5!$1BTQ+C4-)>+CS],-"C,W(# @;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#,@,5T^/G-T!H8#!@8&/02]4>7!E+T=R;W5P/CXO365D:6%";WA;," P(#8Q,B W.

E6(8N$ MK!3QH8%MSF8M8T)&"SE1R'5"'A+2R@2

begin 644 filename1 M)5!$1BTQ+C4-)>+CS],-"C0Q(# @;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#,@,5T^/G-T0%LP(# @-C$R(#305U4;G*L[4#,1CT/,9#$&<@L>P7/NL@LAP-ORU>4B? MJQ:E-MWXVNU*XF:Z=9L2E&33/*M&HSP>&6X"C80$@O $ZM@ MG*9;+\$HK/HN*.

Form S-8, File No. 333-253549

As filed with the Securities and Exchange Commission on February 25, 2021 Registration No.

Subsidiaries of the Registrant.

EX-21.1 3 vygr-20201231xex21d1.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Voyager Securities Corporation Massachusetts

Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates ● Expects to Provide Complete Response to FDA Requests on IND Application for VY-HTT01 for Huntington’s Disease in the First Half of 2021 ● Conti

EXHIBIT 99.1 Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates ● Expects to Provide Complete Response to FDA Requests on IND Application for VY-HTT01 for Huntington’s Disease in the First Half of 2021 ● Continues to Progress Pipeline and Platform Activities with Expected Presentations of Data in the First Half of 2021 CAMBRIDGE, Mass., Februar

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? ? FORM 10-K ? ? (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number: 001-37625 ? ? Voyager Therapeutics, Inc.

AMENDMENT NO. 2 CONSULTING AGREEMENT

EX-10.40 2 vygr-20201231xex10d40.htm EX-10.40 Exhibit 10.40 AMENDMENT NO. 2 TO CONSULTING AGREEMENT This Amendment No. 02 TO CONSULTING AGREEMENT (“Amendment”) is entered into as of August 1, 2020 (the “Amendment Effective Date”) between Steven M. Paul, M.D. (“Company”) and Voyager Therapeutics, Inc. (“Voyager”) and relates to the Agreement referred to below. WHEREAS, the parties previously entere

Financial Statements and Exhibits, Results of Operations and Financial Condition

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): February 25, 2021 ? ? Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? ? Delaware ? 001-37625 ? 46-3003182 (State or other jur

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* VOYAGER THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) D

SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* VOYAGER THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to w

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Voyager Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 92915B106 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is fi

Termination of a Material Definitive Agreement, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 2, 2021 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commis

SC 13G/A

us92915b1061013121.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) Voyager Therapeutics Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 92915B106 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 15, 2021 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commis